Patent US5591828A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5591828A Expired / Lapsed US ⏱️ 0.0 years remaining

Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof

Assignee: Siemens Healthcare Diagnostics GmbH Germany
•
Filing: 1994-09-29
•
Granted: 1997-01-07
•
Expires: 2014-09-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to bispecific and oligospecific, mono- and oligovalent receptors which are prepared by gene manipulation by fusion of DNA coding for F(ab) fragments of antibodies of two or more different specificities by means of suitable linkers. In this connection, one specificity is preferably directed either against an epitope, which is located on the cell membrane or in the interstitium, of a tumor-associated antigen (TAA) or against an epitope in the tumor endothelium (TE), while the other specificities relate to high-molecular or low-molecular weight ligands and react, for example, with the Komplexons ethylenediaminetetraacetate and diethylenetriaminepentaacetate in Y90 complexed form (EDTA-Y90 and DTPA-Y90 respectively). In a particularly preferred embodiment, the binding with the Komplexons takes place on the Komplexon receptor arm via fos-jun interaction (or else avidin-biotin interaction). Other preferred specificities have catalytic properties.

Inventors

  • 👤 Klaus Bosslet
  • 👤 Peter Hermentin
  • 👤 Gerhard Seemann
  • 👤 Ludwig Kuhlmann
  • 👤 Axel Steinstr asser

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-31 01:20
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C07; C07K; C07K16/00; C07K16/46; C07K16/468; A; A61; A61P; A61P35/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3007; A61K; A61K38/00

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 99 words
A bispecific or oligospecific mono- or oligovalent receptor produced by gene manipulation comprising: a) a VH and a CH1 region of a first antibody having an antigen binding specificity; b) a VH and a CH1 region of a second antibody having an antigen binding specificity, wherein the antigen binding specificity of said first antibody is different from the antigen binding specificity of said second antibody; and c) a polypeptide spacer that links the CH1 region of said first antibody to the VH region of said second antibody without impeding association with light chains of said antibodies or antigen binding.
Claim 2
Dependent Claim 99 words
A bispecific or oligospecific mono- or oligovalent receptor produced by gene manipulation comprising: a) a VH and a CH1 region of a first antibody having an antigen binding specificity; b) a VH and a CH1 region of a second antibody having an antigen binding specificity, wherein the antigen binding specificity of said first antibody is different from the antigen binding specificity of said second antibody; and c) a polypeptide spacer that links the CH1 region of said first antibody to the VH region of said second antibody without impeding association with light chains of said antibodies or antigen binding.
Claim 3
Dependent Claim 21 words
A receptor as claimed in claim 1, wherein said receptor further comprises light chains of said first and said second antibodies.
Claim 4
Dependent Claim 11 words
A diagnostic composition comprising a receptor as claimed in claim 2.
Claim 5
Dependent Claim 18 words
A receptor as claimed in claim 2, wherein said first antibody binds to animal or human tumor-associated antigens.
Claim 6
Dependent Claim 15 words
A receptor as claimed in claim 2, wherein said receptor has catalytic or enzymatic activity.
Claim 7
Dependent Claim 26 words
A receptor as claimed in claim 2, wherein said first antibody binds to animal or human tumor-associated antigens and said second antibody binds to a chelate.
Claim 8
Dependent Claim 52 words
A receptor as claimed in claim 2, wherein a variable region of said first antibody comprises an amino acid sequence of V H or V K selected from the group consisting of an amino acid sequence of V H or V K of FIG. 22, FIG. 23, FIG. 24, and FIG. 25.
Claim 9
Dependent Claim 52 words
A receptor as claimed in claim 4, wherein a variable region of said first antibody comprises an amino acid sequence of V H or V K selected from the group consisting of an amino acid sequence of V H or V K of FIG. 22, FIG. 23, FIG. 24, and FIG. 25.
Claim 10
Dependent Claim 52 words
A receptor as claimed in claim 5, wherein a variable region of said first antibody comprises an amino acid sequence of V H or V K selected from the group consisting of an amino acid sequence of V H or V K of FIG. 22, FIG. 23, FIG. 24, and FIG. 25.
Claim 11
Dependent Claim 52 words
A receptor as claimed in claim 6, wherein a variable region of said first antibody comprises an amino acid sequence of V H or V K selected from the group consisting of an amino acid sequence of V H or V K of FIG. 22, FIG. 23, FIG. 24, and FIG. 25.

References Cited (Backward Citations)

US4714681A Cited
US4652440A Cited
WO1986001407A1 Cited
EP0369566A2 Cited
EP1410793A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-01-07 2000-07-08 2001-01-07 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-01-07 2004-07-08 2005-01-07 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-01-07 2008-07-08 2009-01-07 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag